Targovax announces publication of new oncolytic virus data in the Journal of Medical Virology and Cancer Gene Therapy
Validation of ONCOS-102 potential to generate tumor-specific immune responses in vivoOslo, Norway, 12 September 2018 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors, is pleased to note that pre-clinical data from its ONCOS oncolytic virus program has been published in two leading, peer reviewed publications, the Journal of Medical Virology and Cancer Gene Therapy. The first paper, entitled “Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal